A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib

• Mary Clark, MD,
• Paul Imbriano, DO,
• Michael Harwood, MD,
• Klaus Busam, MD,
• Leslie Robinson-Bostom, MD

Affiliations

Mary Clark, MD

Department of Pathology, White River Junction VA Medical Center, White River Junction, Vermont

Paul Imbriano, DO

Department of Surgery, Berkshire Medical Center, Pittsfield, Massachusetts

Michael Harwood, MD

Hartford HealthCare Medical Group Dermatology, Westerly, Rhode Island

Klaus Busam, MD

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

Leslie Robinson-Bostom, MD

Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Correspondence to: Leslie Robinson-Bostom, MD, Department of Dermatology, Warren Alpert Medical School of Brown University, Rhode Island Hospital, 593 Eddy Street, APC-10, RI 02903.